Total
0
Shares
Source: Therma Bright
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Therma Bright (THRM) will begin its U.S. clinical performance study of its AcuVid™ COVID-19 Rapid Antigen Saliva Test after receiving conditional approval from the IRB
  • The clinical performance study will begin immediately at three U.S.-based clinics
  • Results will be delivered to the FDA within the next few weeks
  • Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company
  • Therma Bright Inc. (THRM) opened trading at C$0.395 per share

Therma Bright (THRM) will begin its U.S. clinical performance study with the receipt of the Institutional Review Board’s (IRB) conditional approval.

The clinical performance study will begin immediately at three U.S.-based clinics. The results will complement the Brazilian clinical study and other requested test data that have been submitted to the FDA.

“We’re pleased to have received IRB conditional approval for our U.S. clinical performance study,” shared Rob Fia, CEO of Therma Bright.

“Therma Bright can begin moving forward in our efforts with three pre-selected U.S. clinics. Based on current COVID-19 infection rates, we expect the study results to be delivered to the FDA within the next few weeks, as part of our AcuVid™ application for Emergency Use Authorization (EUA).”

Since mid-July 2021, the company has actively engaged with FDA executives, doctors and scientists on its AcuVid™ COVID-19 Rapid Antigen Saliva Test application, and anticipates Emergency Use Authorization (EUA) following final FDA review.

Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges.

Therma Bright Inc. (THRM) opened trading at C$0.395 per share.

More From The Market Herald
Pluribus Technologies - CEO, Richard Adair.

" Pluribus Technologies completes equity financing

Pluribus Technologies has completed a C$25M equity financing.
The Market Herald Video

" LUXXFOLIO Holdings (CSE:LUXX) provides operational update

LUXXFOLIO Holdings’ (LUXX) November updates includes record mining revenues of approximately $1.8 million and monthly rewards of 23.5 Bitcoin.
Victory Square Technologies - CEO, Shafin Diamond Tejani

" Victory Square Technologies (CSE:VST) to issue the second tranche of dividend

Victory Square (VST) will issue the second tranche of its special dividend of common shares of portfolio company Fantasy 360 Technologies in December

" Upco International (CSE:UPCO) announces Q3 2021 interim financial results

Upco International (UPCO) focused on growing its wholesale telecom business in the third quarter, resulting in higher revenue.